Status:
COMPLETED
Predictive Factors of Long Term Outcome in MMN
Lead Sponsor:
Central Hospital, Nancy, France
Collaborating Sponsors:
Centre Hospitalier Régional Metz-Thionville
Hospices Civils de Lyon
Conditions:
MMN
Eligibility:
All Genders
18+ years
Brief Summary
The cornerstone treatment for multifocal motor neuropathy (MMN), a rare and disabling dysimmune neuropathy, is intravenous immunoglobulin (IVIg). The aim of this study is to identify prognostic factor...
Detailed Description
The cornerstone treatment for multifocal motor neuropathy (MMN), a rare and disabling dysimmune neuropathy, is intravenous immunoglobulin (IVIg). However, 10% of patients progress despite treatment. T...
Eligibility Criteria
Inclusion
- diagnosis of MNN following the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) Guideline criteria 2010
Exclusion
- missing data
- clinical progression features suggested another inflammatory neuropathy,
- immunosuppressive agents for another pathology.
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2019
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT04015934
Start Date
April 1 2018
End Date
February 1 2019
Last Update
July 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Hospital
Nancy, France, 54000